Baxalta, Inc. (BXLT)

Oncology Corporate Profile

HQ Location

One Baxter Parkway
Deerfield, IL 60015

Company Description

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy.

Website: http://www.baxalta.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
pacritinibJAK2/FLT3 dual inhibitorMyelofibrosisIII
imalumab / BAX 069MIF inhibitorColorectal cancerII
Oncaspar_ / pegaspargaseAcute Myelogenous Leukemia (AML)II

View additional information on product candidates here »

Source


http://www.baxalta.com

Recent News Headlines

16 companies we lost in 2016

12/20/2016 07:00 pm

5 Biggest Acquisitions of 2016

12/16/2016 06:00 pm

Baxter Going Strong

8/30/2016 08:00 pm

[$$] Shire lifts guidance as Baxalta spurs strong sales growth

8/2/2016 02:02 pm

[at Financial Times] - Shire, the acquisitive London-listed pharmaceuticals group that specialises in drugs for rare diseases, has reported strong growth across the business and lifted its guidance for the year. The drugmaker ...